VivoSeq
Oncology

Small Cell Lung Carcinoma

16

Pipeline Programs↗

4

Active Trials↗

15

Companies Involved↗

Small Cell Lung Carcinoma is an emerging landscape with 16 programs across 15 companies. The most active players are Suzhou Suncadia Biopharmaceuticals Co., Ltd., McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Imclone. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

56/100

Attrition Rate

31/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

4 programs

Phase 1M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 1I

Imclone

1 program

Phase 1A

Acrotech Biopharma Inc.

1 program

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

2 programs

Phase 2A

Avyxa

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

72%

Small molecule

13 of 18 classified programs — the dominant modality here.

28%ALL OTHERSMonoclonal antibody528%

Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 72% of 25 pipeline programs.

Analysis

Trial Status

13

clinical trials

Completed5 · 38%
Terminated4 · 31%
Recruiting2 · 15%
Not yet recruiting1 · 8%
Active, not recruiting1 · 8%

Clinical Trials

Trial Activity

13 trials

Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma
Recruiting·CCentre Antoine Lacassagne·Phase 1·NCT03467360·27 enrolled
DAREON™-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT05882058·204 enrolled
An Open Label, Multicenter Phase I Clinical Study on the Pharmacokinetics, Safety, Tolerability, and Efficacy of SHR-1316 (SC) Combined With Carboplatin and Etoposide in First-line Treatment of Extensive Stage Small Cell Lung Cancer
Active, not recruiting·Suzhou Suncadia Biopharmaceuticals Co., Ltd. logoSuzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 1·NCT07009457·24 enrolled
REPLAT- A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)
Not yet recruiting·UUniversity of Cologne·Phase 2·NCT07699237·54 enrolled
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
Completed·EETOP IBCSG Partners Foundation·Phase 2·NCT02046733·222 enrolled
A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma
Completed·Eli Lilly logoEli Lilly·Phase 2·NCT01439568·90 enrolled
Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma
Completed·AAGC Biologics S.p.A.·Phase 2·NCT00483509·28 enrolled
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT00207116·120 enrolled
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
Completed·National Cancer Institute (NCI)·Phase 1·NCT00926640·28 enrolled
Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY)
Terminated·—·Phase 2·NCT00324558·39 enrolled
Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma
Terminated·TThreshold Pharmaceuticals·Phase 2·NCT00435578·50 enrolled
Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma
Terminated·GSK logoGSK·Phase 1·NCT02034123·29 enrolled
A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
Terminated·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT00461110·35 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)